Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder
Annals of Pharmacotherapy · 29.07.2026
DOI: 10.1177/10600280261470404 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 29.07.2026. Verfasst von Bradley Phillips und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, USA. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
To review the pharmacology, pharmacokinetics, efficacy, safety, and clinical role of milsaperidone (Bysanti), a newly approved atypical antipsychotic for schizophrenia and acute bipolar I disorder. Data Sources: A comprehensive literature search was conducted using PubMed, Embase, and Google Scholar from database inception through April 2026. Additional data were obtained from Food and Drug Administration prescribing information and pharmacologic references using key terms including milsaperidone, Bysanti, iloperidone, atypical antipsychotics, schizophrenia, and bipolar I disorder. Study Selection and Data Abstraction: English-language studies evaluating milsaperidone or its parent compound, iloperidone, were included, focusing on pharmacologic properties, clinical efficacy, and safety outcomes. Key trials, reviews, and regulatory data were abstracted and synthesized. Data Synthesis: Milsaperidone, the active metabolite of iloperidone, exerts its effects through dopamine D₂ and serotonin 5-HT₂A receptor antagonism, with additional α₁-adrenergic blockade contributing to its safety profile. Clinical evidence demonstrates efficacy in reducing symptoms of schizophrenia and bipolar mania, with low rates of extrapyramidal symptoms and akathisia. However, tolerability concerns include orthostatic hypotension, QTc prolongation, sedation, and weight gain. Pharmacokinetic variability associated with CYP2D6 metabolism and gradual titration remain key considerations. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Milsaperidone expands available atypical antipsychotic options, offering a potentially favorable tolerability profile for patients with prior intolerance or sensitivity to movement-related adverse effects. Careful patient selection and monitoring are essential.
Conclusion
Milsaperidone represents an incremental yet meaningful addition to antipsychotic therapy, supporting individualized strategies in schizophrenia and bipolar I disorder while balancing efficacy and tolerability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, USA.
- WakeMed Physician Practices, WakeMed Raleigh Hospital, NC, USA.
ORCID-Profile: Bradley Phillips, Melanie Horta
Zitieren
APA
Phillips, B., Horta, M., Santini, N., & Chapman, D. (2026). Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261470404
Vancouver
Phillips B, Horta M, Santini N, Chapman D. Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261470404
BibTeX
@article{Phillips2026,
author = {Phillips, Bradley and Horta, Melanie and Santini, Nicole and Chapman, Derek},
title = {Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261470404}
}
EUVIMED